Pryank Patel

Pryank Patel is a Lecturer in Biochemistry at the University of Hertfordshire's School of Life and Medical Sciences within the Department of Clinical, Pharmaceutical and Biological Science. He joined the institution in 2013 and maintains active honorary positions as Research Fellow at Birkbeck College and Lecturer at the University of Liverpool.

His educational background includes:

• PhD in Structural Biology from Birkbeck College (awarded February 15, 2008)
• MSc in Molecular Modelling & Bioinformatics from Birkbeck College (awarded September 1, 2001)
• BSc (Hons) in Biochemistry & Microbiology from Queen Mary University of London (awarded June 1, 2000)

Prior experience includes 2.5 years as Scientific Programmer with CCP4 at Daresbury Laboratory and nearly 6 years as Postdoctoral Research Associate at the University of Liverpool.

Dr. Patel's research centers on structural biology and protein biochemistry with emphasis on nuclear receptors (particularly thyroid hormone receptors), calcium-binding proteins, and their disease implications. His work integrates computational modeling, protein crystallography, and cell-based assays to investigate protein conformational changes, metastasis mechanisms, and drug-receptor interactions, with significant contributions to pancreatic cancer therapeutics and endocrine pharmacology.

Analysis of his 2015-2020 publications reveals consistent focus on molecular disease mechanisms, particularly: 1) Structural characterization of protein switches (e.g., cysteine string protein phosphorylation), 2) Repurposing NSAIDs as nuclear receptor modulators, and 3) Developing anti-metastatic compounds targeting S100P in pancreatic cancer. His methodology bridges wet-lab experimentation with in silico modeling.

No scientific awards were documented in the provided profile.

While specific students and grants aren't listed, his collaborative publication record (including multi-institutional projects with Liverpool and industry partners) indicates active supervision and research funding. Current projects involve enhancing cellular stress tolerance using extremophile proteins and developing novel receptor antagonists.

He operates within the Biosciences Research Group at the Centre for Research in Mechanisms of Disease and Drug Discovery, focusing on interdisciplinary approaches to disease mechanism elucidation and therapeutic development.